Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
-4.32% $2.66
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 68.10 mill |
EPS: | -3.98 |
P/E: | -0.670 |
Earnings Date: | May 12, 2024 |
SharesOutstanding: | 25.60 mill |
Avg Daily Volume: | 0.243 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.670 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.11x |
Company: PE -0.670 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$3.44 (29.41%) $0.782 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 2.40 - 2.98 ( +/- 10.63%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-29 | Mashiach Nissim | Buy | 25 000 | Stock Option (Right to Buy) |
2024-01-29 | Dietz Thomas John | Buy | 30 000 | Stock Option (Right to Buy) |
2024-01-29 | Schilsky Richard | Buy | 25 000 | Stock Option (Right to Buy) |
2024-01-29 | Granfield Christine | Buy | 85 000 | Employee Stock Option (Right to Buy) |
2024-01-29 | Baum Jason | Buy | 85 000 | Employee Stock Option (Right to Buy) |
INSIDER POWER |
---|
66.64 |
Last 95 transactions |
Buy: 11 050 606 | Sell: 1 768 106 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.66 (-4.32% ) |
Volume | 0.192 mill |
Avg. Vol. | 0.243 mill |
% of Avg. Vol | 79.14 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $3.49 | N/A | Active |
---|
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Date | Signal | @ |
---|---|---|
XMRUSD | Mar 28 - 21:45 | $135.23 |
POLYXUSD | Mar 28 - 21:43 | 0.546 |
ATORUSD | Mar 28 - 21:44 | 3.39 |
KUJIUSD | Mar 28 - 21:42 | 2.70 |
ETH2X-FLIUSD | Mar 28 - 21:41 | 31.07 |
PEPECOINUSD | Mar 28 - 21:39 | 5.27 |
XVSUSD | Mar 28 - 21:38 | $16.08 |
BAKEUSD | Mar 28 - 21:38 | $0.449 |
CTXUSD | Mar 28 - 21:38 | 4.86 |
DUSKUSD | Mar 28 - 21:38 | 0.605 |